Former USPTO Head Criticizes Agency’s Approach To Pharma Patents

By Jessica Karins / February 3, 2023 at 4:52 PM
A former director of the United States Patent and Trademark Office is criticizing the agency for its recent request for comments on the patent process for biopharmaceutical products, saying USPTO’s questions unfairly malign pharmaceutical companies and a patent system that works well. The former director spoke with Inside Health Policy on Thursday (Feb. 2), a day after USPTO’s comment deadline and as the Senate Judiciary Committee laid plans to take up long-debated pharmaceutical patent reforms next week . David...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.